ROCK-INDUCED EARLY-ONSET BOWEL CANCER PROGRESSION
Professor Michael Samuel
Head, Tumour Microenvironment Laboratory
Centre for Cancer Biology
SA Pathology and University of South Australia &
Principal Investigator at the Cancer Mechanotherapies Laboratory,
Basil Hetzel Institute for Translational Health Research
Adelaide, South Australia, Australia
RESEARCHER PROFILE
Filmed in Adelaide, South Australia | January 2025
Michael Samuel is a cell biologist whose research interest is in understanding how cancer mechanobiology influences the tumour microenvironment, thereby promoting tumour progression. He is Professor of Matrix Biology at the University of South Australia, Adelaide and heads the Tumour Microenvironment Laboratory at the Centre for Cancer Biology and the Cancer Mechanotherapies Laboratory at the Basil Hetzel Institute for Translational Health Research.
He obtained his Ph.D. from the University of Melbourne in 2004, working with Prof. Matthias Ernst at the Ludwig Institute. He then joined the laboratory of Prof. Mike Olson at the Beatson Institute for Cancer Research, Glasgow, with whom he identified the role of the Rho-ROCK signalling pathway in regulating tumour-promoting mechanical properties of the dermal extracellular matrix. He returned to Australia in 2012 to join the Centre for Cancer Biology as a Laboratory Head.
Discoveries from his laboratory include a role for the ER-stress protein CRELD2 in the recruitment and education of cancer-associated fibroblasts and the roles of Rho-ROCK signalling in the tumour immune microenvironment. He has been awarded an Australian Research Council Future Fellowship, an Emerging Leader Award by the Australia and New Zealand Society for Cell and Developmental Biology (2020), the Barry Preston Award for leadership in the field, by the Matrix Biology Society of Australia and New Zealand (2021) and the Australian Breast Cancer Fellowship by The Hospital Research Foundation (2023).
In April 2024, Bowel Cancer Australia announced a team led by Professor Michael Samuel as the successful applicant for a three-year AUD$600k early-onset bowel cancer research project through the 2023 round of Cancer Australia’s Priority-driven Collaborative Cancer Research Scheme (PdCCRS).
Professor Samuel of the Centre for Cancer Biology (an alliance between the University of South Australia and SA Pathology) and the Basil Hetzel Institute for Translational Health Research are investigating ROCK-induced early-onset bowel cancer progression.
His team will also be examining whether proteins that interact with ROCK cause early-onset bowel cancer progression, and if they do, targeting these proteins would be a way of stopping ROCK from accelerating tumour growth.
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
-
Neonatal respiratory trials in sick & preterm newborn infants
Prof Brett J. Manley leads and collaborates on large national and international randomised clinical trials in neonatology. He previously collaborated on 4 randomised trials of nasal high-flow as non-invasive respiratory support for preterm and term infants, all of which were published in N Engl J Med. Recently he led the PLUSS trial of intratracheal budesonide for extremely preterm infants, that recruited in 21 NICUs across 4 countries, the results of which were published in JAMA. PLUSS was awarded the Australian Clinical Trials Alliance Trial of the Year in 2025. Another passion of his is mentoring and supervising early career researchers to undertake their own clinical trials.
-
Novel forms of brain stimulation & psychedelic assisted psychotherapy
Professor Paul Fitzgerald is the Head of the School of Medicine and Psychology at the Australian National University. He is an academic psychiatrist with a MBBS degree, Masters of Psychological Medicine and research PhD. He has conducted an extensive range of experimental studies and clinical trials, focused on the development of novel treatment options for patients with mental health conditions such as depression, schizophrenia, obsessive compulsive disorder, PTSD, autism and Alzheimer’s disease.
